TRANSGENE (EPA:TNG) | Finanzwire

Basculer en Français

10482	Companies
220830	Keywords
150169	Articles
116820	Press releases

Home
Companies
TRANSGENE

PRESS RELEASE

published on 03/27/2025 at 17:45, 1 year 2 months ago

Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ? Strong Outlook for 2025
Transgene achieves key milestones in 2024, including clinical proof of principle for individualized cancer vaccine TG4050, with strong outlook for 2025. New trial planned in Q4 2025 for a second indication

Milestones Cancer Vaccine Transgene 2025 Outlook Clinical Proof
BRIEF

published on 01/21/2025 at 17:50, 1 year 4 months ago

Transgene Prepares for Biomed Investor Forum

Investors BIOMED Forum Immunotherapy Transgene Viral Vectors
PRESS RELEASE

published on 01/21/2025 at 17:45, 1 year 4 months ago

Transgene to Participate in the Biomed Forum Investor Conference
Transgene's management team to participate in the Biomed Forum Investor Conference in Paris on February 4, 2025

Investor Conference Paris BIOMED Forum Transgene February 4
BRIEF

published on 11/05/2024 at 07:35, 1 year 6 months ago

Transgene and ProBioGen join forces for personalized cancer vaccines

Biotechnology Cancer Transgene ProBioGen Personalized Vaccines
PRESS RELEASE

published on 10/14/2024 at 07:30, 1 year 7 months ago

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers
BRIEF

published on 09/14/2024 at 09:10, 1 year 8 months ago

Transgene and BioInvent: promising results for the oncolytic virus BT-001

Cancer Transgene Oncolytic Virus BioInvent BT-001
PRESS RELEASE

published on 09/14/2024 at 09:05, 1 year 8 months ago

Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
Transgene and BioInvent present promising early results of oncolytic virus BT-001 in ESMO 2024, showing antitumor activity in solid tumors. BT-001 induces tumor regression and enhances T cell infiltration

Transgene Oncolytic Virus BioInvent Antitumor Activity ESMO 2024
BRIEF

published on 09/13/2024 at 10:37, 1 year 8 months ago

Threshold crossing by SITAM Belgium in TRANSGENE SA

Voting Rights Capital Increase Threshold Crossing SITAM Belgium TRANSGENE SA
BRIEF

published on 09/10/2024 at 07:35, 1 year 8 months ago

Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation

Cancer Treatment Oncology Leadership Immunotherapy Transgene
PRESS RELEASE

published on 09/10/2024 at 07:30, 1 year 8 months ago

Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
Transgene appoints Dr. Emmanuelle Dochy as CMO and Dr. Maurizio Ceppi as CSO to drive innovation in cancer immunotherapies. Company progresses clinical pipeline with therapeutic vaccine TG4050

Innovation Oncology Clinical Pipeline Immunotherapy Transgene

Accesswire

Published on 06/02/2026 at 00:00, 1 hour 49 minutes ago

Boron One Announces Financing
Published on 06/01/2026 at 23:57, 1 hour 52 minutes ago

Metallic Minerals Announces Bought Deal LIFE Private Placement for Gross Proceeds of C$8.0 Million
Published on 06/01/2026 at 23:05, 2 hours 44 minutes ago

Faraday Copper Strengthens Team to Support Project Advancement in Arizona
Published on 06/01/2026 at 23:00, 2 hours 49 minutes ago

CCL Industries Closing of Sleever International Acquisition
Published on 06/01/2026 at 22:30, 3 hours 19 minutes ago

Revolve to Present at the Small Cap Growth Virtual Investor Conference on June 4, 2026

View all ACCESSWIRE

EQS Group

Published on 06/01/2026 at 23:00, 2 hours 48 minutes ago

DriveNets Secures $410M Series D to Meet Surging Demand for Ethernet Fabric in Large-Scale AI Deployments
Published on 06/01/2026 at 22:05, 3 hours 43 minutes ago

EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Published on 06/01/2026 at 22:05, 3 hours 44 minutes ago

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
Published on 06/01/2026 at 21:20, 4 hours 29 minutes ago

Eurobattery Minerals: Loft Capital exercises conversion rights – Conversion Threshold Date reached and a total of 23,798,419 new shares to be registered
Published on 06/01/2026 at 19:00, 6 hours 48 minutes ago

Armen Pogossian Represents Armenia at Forbes Under 30 Summit China, Empowering the Next Generation of Global Entrepreneurs

Les Echos

Published on 06/01/2026 at 18:47, 7 hours 1 minute ago

Disclosure of transactions in own shares from May 25 to May 29, 2026
Published on 06/01/2026 at 18:00, 7 hours 49 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 06/01/2026 at 17:54, 7 hours 54 minutes ago

Reporting on share buyback transactions carried out on May 28, 2026
Published on 06/01/2026 at 17:54, 7 hours 54 minutes ago

TF1 - Monthly disclosure of the total number of shares and voting rights - May 2026
Published on 06/01/2026 at 17:45, 8 hours 3 minutes ago

ENGIE secures €1 billion export financing backed by Euler Hermes

View all LES ECHOS COMFI WIRE